{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:49:51Z","timestamp":1782953391667,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16118-8","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:25:52Z","timestamp":1778315152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proclarix\u2019 performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-1295","authenticated-orcid":false,"given":"Ralph","family":"Schiess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8145-8325","authenticated-orcid":false,"given":"Alcibiade","family":"Athanasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6958-5205","authenticated-orcid":false,"given":"Madlen M.E.","family":"Kasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-671X","authenticated-orcid":false,"given":"Torben F","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9522-7023","authenticated-orcid":false,"given":"Gitte E","family":"Kissow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5894-9479","authenticated-orcid":false,"given":"Louise F","family":"Obro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-4714","authenticated-orcid":false,"given":"Jonna S","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7622-8402","authenticated-orcid":false,"given":"Mads H","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-1640","authenticated-orcid":false,"given":"Palle J","family":"Osther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-6394","authenticated-orcid":false,"given":"Ahmed H.","family":"Zedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"16118_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009.","journal-title":"Eur Urol"},{"key":"16118_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11523-022-00925-7","volume":"17","author":"ND Shore","year":"2022","unstructured":"Shore ND, Morgans AK, El-Haddad G, Srinivas S, Abramowitz M. Addressing challenges and controversies in the management of prostate cancer with multidisciplinary teams. Target Oncol. 2022;17:709\u201325. https:\/\/doi.org\/10.1007\/s11523-022-00925-7.","journal-title":"Target Oncol"},{"key":"16118_CR3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"UPST Force","year":"2018","unstructured":"Force UPST, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319:1901\u201313. https:\/\/doi.org\/10.1001\/jama.2018.3710.","journal-title":"JAMA"},{"key":"16118_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2024.04.030","volume":"86","author":"A Krilaviciute","year":"2024","unstructured":"Krilaviciute A, Kaaks R, Seibold P, de Vrieze M, Lakes J, Radtke JP, et al. Risk-adjusted screening for prostate cancer\u2014defining the low-risk group by data from the PROBASE trial. Eur Urol. 2024;86:493\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.030.","journal-title":"Eur Urol"},{"key":"16118_CR5","doi-asserted-by":"publisher","first-page":"e0181557","DOI":"10.1371\/journal.pone.0181557","volume":"12","author":"K Endt","year":"2017","unstructured":"Endt K, Goepfert J, Omlin A, Athanasiou A, Tennstedt P, Guenther A, et al. Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS ONE. 2017;12:e0181557. https:\/\/doi.org\/10.1371\/journal.pone.0181557.","journal-title":"PLoS ONE"},{"key":"16118_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/bco2.8","volume":"1","author":"H Klocker","year":"2020","unstructured":"Klocker H, Golding B, Weber S, Steiner E, Tennstedt P, Keller T, et al. Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer. BJUI Compass. 2020;1:15\u201320. https:\/\/doi.org\/10.1002\/bco2.8.","journal-title":"BJUI Compass"},{"key":"16118_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.euo.2020.12.003","volume":"5","author":"T Steuber","year":"2022","unstructured":"Steuber T, Heidegger I, Kafka M, Roeder MA, Chun F, Preisser F, et al. PROPOSe: a real-life prospective study of proclarix, a novel blood-based test to support challenging biopsy decision-making in prostate cancer. Eur Urol Oncol. 2022;5:321\u20137. https:\/\/doi.org\/10.1016\/j.euo.2020.12.003.","journal-title":"Eur Urol Oncol"},{"key":"16118_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40291-023-00649-y","volume":"27","author":"M Campistol","year":"2023","unstructured":"Campistol M, Triquell M, Regis L, Celma A, de Torres I, Semidey ME, et al. Relationship between proclarix and the aggressiveness of prostate cancer. Mol Diagn Ther. 2023;27:487\u201398. https:\/\/doi.org\/10.1007\/s40291-023-00649-y.","journal-title":"Mol Diagn Ther"},{"key":"16118_CR9","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3390\/cancers14112702","volume":"14","author":"M Campistol","year":"2022","unstructured":"Campistol M, Morote J, Triquell M, Regis L, Celma A, de Torres I, et al. Comparison of proclarix, PSA density and MRI-ERSPC risk calculator to select patients for prostate biopsy after mpMRI. Cancers. 2022;14:2702. https:\/\/doi.org\/10.3390\/cancers14112702.","journal-title":"Cancers"},{"key":"16118_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bju.15998","volume":"132","author":"J Morote","year":"2023","unstructured":"Morote J, Pye H, Campistol M, Celma A, Regis L, Semidey M, et al. Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging. BJU Int. 2023;132:188\u201395. https:\/\/doi.org\/10.1111\/bju.15998.","journal-title":"BJU Int"},{"key":"16118_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.euros.2021.12.009","volume":"37","author":"J Morote","year":"2022","unstructured":"Morote J, Campistol M, Triquell M, Celma A, Regis L, de Torres I, et al. Improving the early detection of clinically significant prostate cancer in men in the challenging prostate imaging-reporting and data system 3 category. Eur Urol Open Sci. 2022;37:38\u201344. https:\/\/doi.org\/10.1016\/j.euros.2021.12.009.","journal-title":"Eur Urol Open Sci"},{"key":"16118_CR12","doi-asserted-by":"publisher","first-page":"0","DOI":"10.5534\/wjmh.210117","volume":"40","author":"J Morote","year":"2021","unstructured":"Morote J, Campistol M, Celma A, Regis L, de Torres I, Semidey ME, et al. The efficacy of proclarix to select appropriate candidates for magnetic resonance imaging and derived prostate biopsies in men with suspected prostate cancer. World J Men\u2019s Heal. 2021;40:0. https:\/\/doi.org\/10.5534\/wjmh.210117.","journal-title":"World J Men\u2019s Heal"},{"key":"16118_CR13","volume-title":"EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Milan 2023","author":"N Mottet","year":"2023","unstructured":"Mottet N, Cornford P, Bergh RCN, van den, Briers E, UOMO) EPA, European PCC, Eberli D, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. Edn. presented at the EAU Annual Congress Milan 2023. Arnhem, the Netherlands: EAU Guidelines Office; 2023."},{"key":"16118_CR14","unstructured":"Danish Multidisciplinary Cancer Groups. Staging of prostate cancer. 2026. https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/daproca\/stadieinddeling-af-prostatacancer\/. Accessed 3 May 2026."},{"key":"16118_CR15","doi-asserted-by":"publisher","first-page":"e0233442","DOI":"10.1371\/journal.pone.0233442","volume":"15","author":"A Macagno","year":"2020","unstructured":"Macagno A, Athanasiou A, Wittig A, Huber R, Weber S, Keller T, et al. Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer. PLoS ONE. 2020;15:e0233442. https:\/\/doi.org\/10.1371\/journal.pone.0233442.","journal-title":"PLoS ONE"},{"key":"16118_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","volume":"61","author":"MJ Roobol","year":"2012","unstructured":"Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61:577\u201383. https:\/\/doi.org\/10.1016\/j.eururo.2011.11.012.","journal-title":"Eur Urol"},{"key":"16118_CR17","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Pi\u00f1eiro L, Tabernero A, Contreras T, Madero R, Lozano D, L\u00f3pez-Tello J, et al. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng\/ml. Eur Urol. 2000;37:289\u201396. https:\/\/doi.org\/10.1159\/000052358.","DOI":"10.1159\/000052358"},{"key":"16118_CR18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/(sici)1097-0258(19980430)17:8<891::aid-sim780>3.0.co;2-b","volume":"17","author":"T Tango","year":"1998","unstructured":"Tango T. Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med. 1998;17:891\u2013908. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19980430)17:8%3C891::aid-sim780%3E3.0.co;2-b.","journal-title":"Stat Med"},{"key":"16118_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1191\/1740774506cn147oa","volume":"3","author":"CS Moskowitz","year":"2006","unstructured":"Moskowitz CS, Pepe MS. Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs. Clin Trials. 2006;3:272\u20139.","journal-title":"Clin Trials"},{"key":"16118_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837. https:\/\/doi.org\/10.2307\/2531595.","journal-title":"Biometrics"},{"key":"16118_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1109\/lsp.2014.2337313","volume":"21","author":"X Sun","year":"2014","unstructured":"Sun X, Xu W. Fast implementation of delong\u2019s algorithm for comparing the areas under correlated receiver operating characteristic curves. Ieee Signal Proc Let. 2014;21:1389\u201393. https:\/\/doi.org\/10.1109\/lsp.2014.2337313.","journal-title":"Ieee Signal Proc Let"},{"key":"16118_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/nejm197507312930513","volume":"293","author":"TJ Fagan","year":"1975","unstructured":"Fagan TJ. Nomogram for Bayes\u2019s Theorem. N Engl J Med. 1975;293:257\u2013257. https:\/\/doi.org\/10.1056\/nejm197507312930513.","journal-title":"N Engl J Med"},{"key":"16118_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989x06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision Curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26:565\u201374. https:\/\/doi.org\/10.1177\/0272989x06295361.","journal-title":"Med Decis Mak"},{"key":"16118_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1046\/j.1525-1497.2000.90907.x","volume":"10","author":"RM Hoffman","year":"2020","unstructured":"Hoffman RM, Clanon DL, Littenberg B, Frank JJ, Peirce JC. Previous studies have demonstrated the limitations of %fPSA, particularly its low specificity, which can lead to a higher rate of unnecessary biopsies. J Gen Intern Med. 2020;10:739\u201348. https:\/\/doi.org\/10.1046\/j.1525-1497.2000.90907.x.","journal-title":"J Gen Intern Med"},{"key":"16118_CR25","doi-asserted-by":"publisher","unstructured":"Khoo A, Liu LY, Nyalwidhe JO, Semmes OJ, Vesprini D, Downes MR, et al. Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. Nat Rev Urol. 2021;1\u201318. https:\/\/doi.org\/10.1038\/s41585-021-00500-1.","DOI":"10.1038\/s41585-021-00500-1"},{"key":"16118_CR26","doi-asserted-by":"publisher","first-page":"1429831","DOI":"10.3389\/fsurg.2024.1429831","volume":"11","author":"S Li","year":"2024","unstructured":"Li S, Zha M, Wang Q, Tang Y. Advances in multiparametric magnetic resonance imaging combined with biomarkers for the diagnosis of high-grade prostate cancer. Front Surg. 2024;11:1429831. https:\/\/doi.org\/10.3389\/fsurg.2024.1429831.","journal-title":"Front Surg"},{"key":"16118_CR27","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.eururo.2007.09.036","volume":"52","author":"K Bensalah","year":"2007","unstructured":"Bensalah K, Montorsi F, Shariat SF. Challenges of Cancer Biomarker Profiling. Eur Urol. 2007;52:1601\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2007.09.036.","journal-title":"Eur Urol"},{"key":"16118_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.euo.2023.10.029","volume":"7","author":"T Kawada","year":"2024","unstructured":"Kawada T, Shim SR, Quhal F, Rajwa P, Pradere B, Yanagisawa T, et al. Diagnostic accuracy of liquid biomarkers for clinically significant prostate cancer detection: a systematic review and diagnostic meta-analysis of multiple thresholds. Eur Urol Oncol. 2024;7:649\u201362. https:\/\/doi.org\/10.1016\/j.euo.2023.10.029.","journal-title":"Eur Urol Oncol"},{"key":"16118_CR29","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","volume":"61","author":"JI Epstein","year":"2012","unstructured":"Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61:1019\u201324. https:\/\/doi.org\/10.1016\/j.eururo.2012.01.050.","journal-title":"Eur Urol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16118-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16118-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16118-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:42:46Z","timestamp":1782952966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16118-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16118"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16118-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Committees on Health Research Ethics for Southern Denmark (S-20220048) and by the Danish Data Protection Agency according to Danish law (24\/38777). All participants in this study provided informed written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Some of the authors received\/held stock options and salaries (AA, MK, RS) and founder shares (RS) of the Proteomedix. AA and RS are inventors of the following patent application (WO2018011212), as are RS on the patent application (WO2009138392).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"801"}}